Moderna Plans to Slash R&D Budget and Prioritize Commercial Business
Thursday, 12 September 2024, 09:34
Key Changes in Moderna's Strategy
Moderna's executives have announced that they anticipate a substantial reduction in research and development spending as they shift priorities. This move comes in light of recent trends in the pharmaceutical sector aimed at enhancing profitability.
Impact on Research and Development
- Reduction in Annual R&D Budget: The budget is expected to decrease by approximately $1.1 billion starting from 2027.
- Shift to Commercial Focus: The company aims to direct resources toward expanding its commercial capabilities, which may lead to increased revenue streams.
This significant budget cut emphasizes the need for companies like Moderna to adapt to changing market conditions and focus on strong commercial viability.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.